To provide international consensus on the use of long-acting growth hormone (LAGH) therapy in children with growth hormone deficiency (GHD) and to guide practitioners in treatment decisions, while emphasizing the need for ongoing research.
Key Findings:
LAGH therapies offer reduced injection frequency and treatment burden compared to daily GH injections.
Improved adherence and treatment outcomes may be associated with LAGH due to lower perceived treatment burden.
Current data on LAGH in pediatric GHD are primarily from clinical trials, with a significant lack of long-term real-world data.
Interpretation:
LAGH formulations may enhance adherence and quality of life for children with GHD, but the lack of real-world data necessitates further research to support these findings and refine treatment guidelines.
Limitations:
Limited long-term data on LAGH efficacy and safety in real-world settings.
Consensus recommendations are based on expert opinion and available clinical trial data, which may not encompass all patient populations and could introduce bias.
Conclusion:
The consensus provides a framework for the use of LAGH in pediatric GHD, emphasizing the need for ongoing research to address existing knowledge gaps and improve treatment guidelines.
by Aristides Maniatis, Wayne Cutfield, Mehul Dattani, Cheri Deal, Paulo Ferrez Collett-Solberg, Reiko Horikawa, Mohamad Maghnie, Bradley S Miller, Michel Polak, Lars Sävendahl, Joachim Woelfle
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
